Drug Profile
Research programme: subcutaneous allergy immunotherapies - Allergy Therapeutics
Alternative Names: Japanese cedar allergy vaccine - Allergy TherapeuticsLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Allergy Therapeutics
- Class Allergy immunotherapies; Antiallergics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Allergic rhinitis
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 19 Dec 2014 No development reported - Preclinical for Allergic rhinitis (Prevention) in United Kingdom (SC)
- 15 Jan 2010 Preclinical development is ongoing in the United Kingdom for an SC injection-based immunotherapy against allergic rhinitis caused by Japanese cedar pollen allergen
- 01 Feb 2007 Preclinical development is ongoing for SC injection-based immunotherapies against allergy arising from Japanese cedar pollen allergen